NVO: Novo Nordisk A/S - Summary | Jitta

Novo Nordisk A/S

NYSE:NVO

Price
$123.49
Loss Chance
42.7%
8.10JITTA SCORE
> 1,000%Over Jitta Line
Jitta Ranking
46 / 1,127
519 / 4,938
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (75)
Recent Business Performance (98)
Financial Strength (95)
Return to Shareholders (87)
Competitive Advantage (84)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Operating MarginExpansion
Debt LevelLow Long Term Debt
Return on EquityConsistently High
Dividend PayoutEvery year
SG&A to SalesDecreasing
Revenue and EarningRevenue decline from 2020-2023
New Share IssuedMore than 50% in 5 years
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
8.10
> 1,000%
2.10
194.51%
2.06
244.26%
Pharmaceuticals
6.91
46.87%
3.25
47.20%
3.88
30.11%
COMPANY DESCRIPTION
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.